^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1

    i
    Other names: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1, VSV-IFNb-TYRP1, Recombinant VSV-expressing IFN-b and TYRP1, Recombinant VSV-IFNbetaTYRP1, VSV-IFN-b/TYRP1, VSV-IFNbetaTYRP1
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    TYRP1 inhibitor, IFNβ stimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. (PubMed, Front Immunol)
    Our study found that VSV-IFNβ -TYRP1 can be safely administered via intratumoral (IT) and IV routes in a previously treated population of patients with MUM. Although there were no clear objective radiographic responses to VSV-IFNβ-TYRP1, dose-dependent immunogenicity to TYRP1 and other melanoma antigens was seen.
    P1 data • Journal • Oncolytic virus
    |
    IFNG (Interferon, gamma) • TYRP1 (Tyrosinase Related Protein 1) • IFNB1 (Interferon Beta 1)
    |
    Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
    over1year
    Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Apr 2024 --> Jan 2027 | Trial primary completion date: Apr 2024 --> Jan 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
    over1year
    Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
    almost2years
    Phase I trial of vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 (VSV-IFNb-TYRP1) in metastatic ocular melanoma (AACR 2023)
    While OV response alone is not sufficient for clinical benefit, the evidence of epitope spreading is encouraging. Future studies of VSV-IFNb-TYRP1 will evaluate combinations with other therapies.
    P1 data • Metastases
    |
    TYRP1 (Tyrosinase Related Protein 1) • IFNB1 (Interferon Beta 1)
    |
    Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
    over2years
    Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov)
    P1, N=72, Suspended, Mayo Clinic | Trial completion date: Mar 2022 --> Apr 2023 | Recruiting --> Suspended | Trial primary completion date: Mar 2022 --> Apr 2023
    Trial completion date • Trial suspension • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 • Voyager-V1